The Ministry of Health and Prevention (MoHAP) in the UAE has withdrawn batch number ME051 of the API Sinocort Nasal Spray, a medication that's used to treat asthma and blocked airways.
The spray is manufactured by Amman Jordan Pharmaceutical Industries.
In a statement, MoHAP said the decision was made after a review of the batch showed it had failed to conform to the approved specifications.
Pharmacists and healthcare providers have been ordered to withdraw it from sale and return the drug to the suppliers
Users are advised to dispose of the batch and report any adverse reactions.
Dr. Amin Hussein Al Amiri, Assistant Undersecretary of the Ministry of Health and Prevention’s Public Health Policy and Licenses, and Chairman of the Supreme National Committee for Pharmacovigilance, urged people to contact them by email at ph@moh.gov.ae, through the E-system on MoHAP’s website, or the smart app ‘UAE RADAR.’
UAE carries out new medical evacuation from Gaza Strip
IRENA Council meets in Abu Dhabi to drive global energy transition
H.H. Sheikh Mohammed unveils body to 'empower volunteering, promote goodness'
'Don't click on 50% discount deals': Dubai Opera warns of fake tickets scam
UAE President, European Council chief stress need to maintain Gaza ceasefire
H.H. Sheikh Ahmed hails national media as crucial pillar of development
Sheikha Bodour Al Qasimi appointed UNESCO Goodwill Ambassador
UAE unveils first Green Innovation District at Expo City
